Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19676973 | 0.93 | MEN1 (0.46) | MEN1KMT2ANPC1RAB9AMAPT | |
| SCHEMBL779443 | 0.87 | NPC1 (0.58) | NPC1RAB9AMAPTMAPK1LMNA | |
| SCHEMBL12936023 | 0.81 | MEN1 (0.48) | MEN1KMT2ACYP19A1GRIN2DGRIN3B | |
| SCHEMBL4787209 | 0.80 | MEN1 (0.52) | MEN1KMT2ACYP19A1NPSR1SLC6A2 | |
| SCHEMBL6280416 | 0.80 | KMT2A (0.52) | MEN1KMT2ACYP19A1NPSR1SLC6A2 | |
| SCHEMBL20820742 | 0.80 | NPC1 (0.53) | NPC1RAB9AMAPTMAPK1LMNA | |
| SCHEMBL13930871 | 0.80 | MEN1 (0.52) | MEN1KMT2ACYP19A1NPSR1SLC6A2 | |
| SCHEMBL10837089 | 0.80 | MEN1 (0.52) | MEN1KMT2ACYP19A1GRIN2DGRIN3B | |
| SCHEMBL5552840 | 0.79 | NPC1 (0.52) | NPC1RAB9AMAPTMAPK1LMNA | |
| SCHEMBL3625528 | 0.79 | NPC1 (0.52) | NPC1RAB9AMAPTMAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| EP-4134076-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | Redhill Biopharma Ltd. (IL) | 2023-02-15 | — | — | EP | disclosed |
| US-11571423-B2 | Small molecule modulators of human sting | CURADEV PHARMA LIMITED (GB) | 2023-02-07 | — | — | US | disclosed |
| US-20230028700-A1 | CHIRAL GUANIDINES, SALTS THEREOF, METHODS OF MAKING CHIRAL GUANIDINES AND SALTS THEREOF, AND USES OF CHIRAL GUANIDINES AND SALTS THEREOF IN THE PREPARATION OF ENANTIOMERICALLY PURE AMINO ACIDS | FU RUI (CA) | 2023-01-26 | — | — | US | disclosed |
| US-20230020373-A1 | 3-N-CYCLOPROPYLMETHYL-2-FLUOROBENZAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | CAC NANTONG CHEMICAL CO., LTD (CN) | 2023-01-19 | — | — | US | disclosed |
| US-11377422-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11111253-B2 | 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-09-07 | — | — | US | disclosed |
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-7615316-B2 | Nonaqueous electrolytic solution and lithium secondary batteries | UBE INDUSTRIES, LTD. (JP) | 2009-11-10 | — | — | US | disclosed |
| US-20080280953-A1 | Agents Used for the Treatment of Seeds | BAYER CROPSCIENCE AG (DE) | 2008-11-13 | — | — | US | disclosed |
| US-7441883-B2 | Production process of inkjet ink composition and inkjet composition | FUJIFILM CORPORATION (JP) | 2008-10-28 | — | — | US | disclosed |
| EP-1361622-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERIES | UBE INDUSTRIES (JP) | 2008-06-04 | — | — | EP | disclosed |
| US-20080050658-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERIES | UBE INDUSTRIES, LTD. (JP) | 2008-02-28 | — | — | US | disclosed |
| US-7294436-B2 | Nonaqueous electrolytic solution and lithium secondary batteries | UBE INDUSTRIES, LTD. (JP) | 2007-11-13 | — | — | US | disclosed |
| CN-1249840-C | Nonaqueous electrolyte solution and lithium secondary battery | UBE INDUSTRIES (JP) | 2006-04-05 | — | — | CN | disclosed |
| US-20040121239-A1 | Nonaqueous electrolytic solution and lithium secondary batteries | UBE INDUSTRIES, LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| CN-1498438-A | Nonaqueous electrolyte solution and lithium secondary battery | ��˲���ʽ���� | 2004-05-19 | — | — | CN | disclosed |
| EP-1361622-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERIES | Ube Industries, Ltd. (JP) | 2003-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111253-B2 | 6-aryl-7-substituted-3-(1H-pyrazol-5-yl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the STAT3 pathway with anti-proliferative activity | STAT3, STAT1, STAT5A | MEN1 4556/4885KMT2A 1893/4885NPC1 3995/4885 |
| US-20080280953-A1 | Agents Used for the Treatment of Seeds | TUBB3, TUBB, GUSB | MEN1 4555/4885KMT2A 3747/4885NPC1 2200/4885 |
| US-11377422-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | MEN1 3082/4885KMT2A 2429/4885NPC1 399/4885 |
| US-11571423-B2 | Small molecule modulators of human sting | STING1, IRF3, CGAS | MEN1 2986/4885KMT2A 4153/4885NPC1 2220/4885 |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | MEN1 688/4885KMT2A 2929/4885NPC1 194/4885 |
| US-20230028700-A1 | CHIRAL GUANIDINES, SALTS THEREOF, METHODS OF MAKING CHIRAL GUANIDINES AND SALTS THEREOF, AND USES OF CHIRAL GUANIDINES AND SALTS THEREOF IN THE PREPARATION OF ENANTIOMERICALLY PURE AMINO ACIDS | GMPS, GUCY1A2, GUCY1B2 | MEN1 3149/4885KMT2A 3227/4885NPC1 2283/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | MEN1 3082/4885KMT2A 2429/4885NPC1 399/4885 |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | MEN1 317/4885KMT2A 2463/4885NPC1 4526/4885 |
| US-20230020373-A1 | 3-N-CYCLOPROPYLMETHYL-2-FLUOROBENZAMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | CYP51A1, DDT, CYP4F11 | MEN1 504/4885KMT2A 637/4885NPC1 1956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.